Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.
复制标题
DOI：
10.1007/s13300-017-0273-4
复制
发表时间：
2017-08
期刊：
影响因子：
--
通讯作者：
Vekov T
中科院分区：
文献类型：
--
作者：
Filipova E;Uzunova K;Kalinov K;Vekov T
2型糖尿病患者患膀胱癌的风险增加。据说吡格列酮会进一步增加它，尽管已发表的证据好坏参半。我们进行了一项荟萃分析，以确定使用吡格列酮和膀胱癌风险增加之间是否存在任何联系，通过电子数据库和临床试验数据登记系统进行了全面的文献检索，以确定研究吡格列酮对糖尿病患者膀胱癌的影响。我们使用研究提供的风险比（RR）和风险比（HR）来说明实验组与对照组相比发生膀胱癌的风险。14项使用RR的研究和12项使用HR的研究被纳入分析。总体RR为1.13，95% CI（0.96-1.33），使用RR的研究之间的异质性较低，表明吡格列酮的使用与膀胱恶性肿瘤风险之间不存在联系。总结HR为1.07（0.96-1.18），使我们能够确认长期使用吡格列酮与膀胱癌之间无关联。我们的研究结果支持吡格列酮组和非使用者组膀胱癌发病率无差异的假设。我们的结论是，膀胱恶性肿瘤的假设风险增加的解释应归因于其他因素。 公司名称：Tchaikapharma High Quality Medicines Inc.本文的在线版本（doi：10.1007/s13300-017-0273-4）包含补充材料，可供授权用户使用。
People with type 2 diabetes are at increased risk of bladder cancer. Pioglitazone is said to increase it further, although published evidence is mixed. We conducted a meta-analysis to determine if any link between the use of pioglitazone and an increased risk of bladder cancer can be found. A comprehensive literature search was conducted through electronic databases as well as registries for data of clinical trials to identify studies that investigate the effect of pioglitazone on bladder cancer in diabetic patients. We used the risk ratio (RR) and the hazard ratio (HR) provided by the studies to illustrate the risk of occurrence of bladder cancer in the experimental group compared to that in the control group. Fourteen studies using RR and 12 studies using HR were included in the analysis. The overall RR was 1.13 with 95% CI (0.96–1.33) with low heterogeneity among the studies using RR, suggesting that no connection exists between use of pioglitazone and the risk of bladder malignancy. The summary HR was 1.07 (0.96–1.18) allowing us to affirm that there is no link between long-term use of pioglitazone and bladder cancer. Our results support the hypothesis of no difference in the incidence of bladder cancer among the pioglitazone group and the nonuser group. Our conclusion is that the explanation of hypothetically increased risk of bladder malignancy should be attributed to other factors. Funding : Tchaikapharma High Quality Medicines Inc. The online version of this article (doi:10.1007/s13300-017-0273-4) contains supplementary material, which is available to authorized users.
登录
查看更多内容
影响因子：
2.4
作者：
Kakehi, Yoshiyuki;Hirao, Yoshihiko;Yokomizo, Akira
通讯作者：
Yokomizo, Akira
影响因子：
168.9
作者：
Dormandy, JA;Charbonnel, B;Taton, J
通讯作者：
Taton, J
影响因子：
8.2
作者：
Levin, Daniel;Bell, Samira;Colhoun, Helen M.
通讯作者：
Colhoun, Helen M.
影响因子：
5
作者：
Coughlin, SS;Calle, EE;Thun, MJ
通讯作者：
Thun, MJ
一项关于发现吡格列酮与印度人群中膀胱癌的相关性的回顾性研究。
影响因子：
--
作者：
Balaji V;Seshiah V;Ashtalakshmi G;Ramanan SG;Janarthinakani M
通讯作者：
Janarthinakani M